These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6133202)

  • 1. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
    Hamblin MW; Creese I
    Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
    Lévesque D; Di Paolo T
    Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
    Hess EJ; Norman AB; Creese I
    J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic uridine treatment reduces the level of [3H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours.
    Farabegoli C; Merlo Pich E; Cimino M; Agnati LF; Fuxe K
    Acta Physiol Scand; 1988 Feb; 132(2):209-16. PubMed ID: 2906500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery.
    Battaglia G; Norman AB; Newton PL; Creese I
    J Neurochem; 1986 Feb; 46(2):589-93. PubMed ID: 2934516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways.
    Undie AS; Berki AC; Beardsley K
    Neuropharmacology; 2000; 39(1):75-87. PubMed ID: 10665821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent differences in the rate of recovery of striatal dopamine D1 and D2 receptors after inactivation with EEDQ.
    Crawford CA; Rowlett JK; McDougall SA; Bardo MT
    Eur J Pharmacol; 1994 Feb; 252(2):225-31. PubMed ID: 8157063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
    Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
    J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gangliosides facilitate the recovery of behavioral response mediated by dopaminergic sites following their irreversible blockade.
    Keller EA; Molina VA
    Brain Res Bull; 1993; 31(1-2):161-3. PubMed ID: 8453485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
    Hess EJ; Battaglia G; Norman AB; Creese I
    Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denervation accelerates the reappearance of neostriatal D-2 receptors after irreversible receptor blockade.
    Neve KA; Loeschen S; Marshall JF
    Brain Res; 1985 Mar; 329(1-2):225-31. PubMed ID: 3156659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo partial inactivation of dopamine D1 receptors induces hypersensitivity of cortical dopamine-sensitive adenylate cyclase: permissive role of alpha 1-adrenergic receptors.
    Trovero F; Hervé D; Blanc G; Glowinski J; Tassin JP
    J Neurochem; 1992 Jul; 59(1):331-7. PubMed ID: 1351927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade.
    Henry JM; Roth GS
    Life Sci; 1984 Aug; 35(8):899-904. PubMed ID: 6482680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of the reversible dopamine antagonist flupenthixol are not potentiated by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in the preweanling rat.
    McDougall SA; Bolanos CA
    Pharmacol Biochem Behav; 1995 Jan; 50(1):127-31. PubMed ID: 7700948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral recovery after irreversible inactivation of D-1 and D-2 dopamine receptors.
    Meller E; Bordi F; Bohmaker K
    Life Sci; 1989; 44(15):1019-26. PubMed ID: 2564615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related differential recovery rates of rat striatal D-1 dopamine receptors following irreversible inactivation.
    Battaglia G; Norman AB; Creese I
    Eur J Pharmacol; 1988 Jan; 145(3):281-90. PubMed ID: 2895004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontogenetic differences in the effects of EEDQ on dopamine-mediated behaviors.
    Mestlin M; McDougall SA
    Pharmacol Biochem Behav; 1993 Aug; 45(4):797-802. PubMed ID: 8105488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats.
    Ekman A; Eriksson E
    Life Sci; 1991; 48(4):321-31. PubMed ID: 1824955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.
    Ekman A; Eriksson E
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):152-7. PubMed ID: 1360151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
    Morissette M; Lévesque D; Di Paolo T
    Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.